Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients

Mycoses

Volumn 39, Issue 5-6, 1996, Pages 185-193

  Andström, Eva Ekelöf ^a   Ringden O ^a   Remberger, M ^a   Svahn, B M ^a   Tollemar, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adverse effects; AmBisome; Amphotericin B; Antimycotic chemotherapy; Bone marrow transplantation; Efficacy; Liposomal formulation; Opportunistic mycoses; Safety

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FLUCYTOSINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHOLECYSTITIS; DISORIENTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DYSPNEA; HUMAN; HYPERKALEMIA; HYPERNATREMIA; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MYCOSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; URTICARIA;

EID: 10144245926     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.1996.tb00123.x     Document Type: Article

References (25)

1. Meyers, J. D. (1990) Fungal infections in bone marrow transplant patients. Semin. Oncol. 17(3), (Suppl. 6), 10-13.
2. Denning, D. W. (1991) Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J. Antimicrob. Chemother. 28 (Suppl. B), 1-16.
3. Tollemar, J. (1991) Invasive fungal infections - incidence, diagnosis, risk-factors and treatment in bone marrow and liver transplant recipients. Thesis. Karolinska Institute, Stockholm, Sweden.
4. Hay, R.J. (1991) Overview of the treatment of disseminated fungal infections. J. Antimicrob. Chemother. 28 (Suppl. B), 17-25.
5. Clift, R. A. (1984) Candidiasis in the transplant patient. Am. J. Med. 77, 34-38.
6. Tollemar, J., Ringdén, O. & Tydén, G. (1990) Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin. Transplant. 4, 167-175.
7. Meunier, F., Prentice, H. G. & Ringdén, O. (1991) Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28 (Suppl. B), 83-91.
8. Hay, R. J. (1994) Liposomal amphotericin B, AmBisome. J. infect. 28, (Suppl. 1), 35-43.
9. Mills, W., Chopra, R., Linch, D. C. & Goldstone, A. H. (1994) Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single centre experience of 133 episodes in 116 patients. Br. J. Haematol. 86, 754-760.
10. Ringdén, O., Meunier, F., Tollemar, J., et al. (1991) Efficacy of Amphotericin B encapsulated in liposomes (AmBisome) in treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother 28 (Suppl. B), 73-82.
11. Ringdén, O., Pihlstedt, P., Markling, L., et al. (1991) Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant. 7, 21-26.
12. Ringdén, O., Bolme, P., Önnqvist, B., et al. (1989) Bone marrow transplantation in children. Clin. Transplant. 3, 12-18.
13. Young, R. C., Bennet, J. E., Geelhold, G. W., et al. (1974) Fungemia with compromized host resistance. A study of 70 cases. Ann. Intent. Med. 80, 605-612.
14. Tollemar, J., Ringdén, O., Andersson. S.. et at. (1993) Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infection in bone marrow transplant recipients. Bone Marrow Transplant. 12, 577-582.
15. Laing, R. B. S., Milne, L. J. R., Leen, C. L. S., et al (1994) Anaphylactic reactions to liposomal amphotericin (letter), Lancet 344, 682.
16. Ringdén, O., Andström, E., Remberger, M., et al. ( 1994) Allergic reactions and other rare side-effects of liposomal amphotericin (letter). Lancet 344, 1156-1157.
17. Denning, D. W. & Stevens. D. A. (1990) Amtifungal and surgical treatment of invasive aspergillosis: review of 2.121 published cases. Rev. Infect. Dis. 2. 1147-1201.
18. Christiansen, K. J., Bernard, E. M., Gold. J. W. M., et al. (1985) Distribution and activity of amphotericin B in humans. J. Infect. Du. 152, 1037-1043.
19. Bjerke, J. W., Meyers, J. D. & Bowden, R. A. (1994) Hepatosplenic candidiasis a contraindication to marrow transplantation? Blood 84, 2811-2814.
20. Goodrich, J. M., Reed, E. C., Mori, M., et al. (1991) Clinical features and analysis of risk factors for invasive Candida infection after marrow transplantation. J. Infect. Dis. 164, 731-740.
21. Neumunaitis, J., Meyers, J. D., Buckner, C. D., et al. (1991) Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 78, 907-931.
22. Petros, W. P., Rabinowitz, J., Stuart, A., et al. (1994) Elevated endogenous serum macrophage colony-stimulating factor in the early stage of fungemia following bone marrow transplantation. Exp. Hematol. 22, 582-586.
23. Jense, J., Warner, T. & Balish, E. (1993) Resistance of SCID mice to Candida albicans administered intravenously or colonizing the gut: role of polymorphonuclear leuko-cytes and macrophages. J. Inject. Dis. 167, 912-919.
24. Jensen, J., Warner, T. & Balish, E. (1994) The role of phagocytic cells in resistance to disseminated candidiasis in granulocytopenic mice. J. Infect. Dis. 170, 900-905.
25. Ringdén, O., Bäckmann, L., Lönnquist, B., et al. (1986) A randomized trial comparing the use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant. 1, 41-51.